Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Blood (2024) 144 (Supplement 1): 4417.

https://doi.org/10.1182/blood-2024-204513

Published: 2024

Journal Articles

Efficacy of Zanubrutinib Combined with Immunochemotherapy in Newly Diagnosed MYD88-Mutated Diffuse Large B-Cell Lymphoma: A Retrospective Single-Center Study

Wenrong Huang, Xiubin Xiao, Xilin Chen, Shunzong Yuan, Yi Ma, Shihua Zhao, Yun Lu, Junli Chen, Nana Cheng, Hua Yin, Feng Pan, Yueqi Wang

Blood (2024) 144 (Supplement 1): 6528.

https://doi.org/10.1182/blood-2024-201880

Published: 2024

Journal Articles

Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R 2 ) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study

Wei Wang, Xu Zhang, Qihui Li, Hua Yin, Xiubin Xiao, Jian Li, Wenrong Huang, Hongmei Jing, Yan Zhang

Blood (2024) 144 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2024-198294

Published: 2024

Journal Articles

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Lin Gui, Keshu Zhou, Ting Liu, Yan Qin, Hongmei Jing, Wenyu Li, Yajun Li, Wenrong Huang, Zhen Wang, Xiuhua Sun, Quan Li, Faming Zhang, Henry Li, Lei Zhang, Peng Sun, Xinbao Gao, Yuankai Shi

Blood (2024) 144 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2024-194771

Published: 2024

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Blood (2024) 144 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2024-201978

Published: 2024

Journal Articles

Daratumumab Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Yi Ma, Xiubin Xiao, Shunzong Yuan, Xilin Chen, Shihua Zhao, Nana Cheng, Yun Lu, Junli Chen, Yueqi Wang, Wenrong Huang

Blood (2023) 142 (Supplement 1): 6687.

https://doi.org/10.1182/blood-2023-184811

Published: 2023

Journal Articles

Upfront Autologous Stem Cell Transplant at First Complete Remission in Patients with Advanced-Stage Extra-Nodal NK/T Cell Lymphoma: A Multicenter Retrospective Study

Shaoxuan Hu, Linjun Zhao, Weiping Liu, Wenrong Huang, Shunan Qi, Xiaopei Wang, Yuqin Song, Yexiong Li, Jun Zhu

Blood (2023) 142 (Supplement 1): 3597.

https://doi.org/10.1182/blood-2023-184486

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: Psychological Burden and Influencing Factors from Mycosis Fungoides and Sézary Syndrome Patients in China

Tun-Ying Hsu, Huiping Sun, Zhiming Li, Wenrong Huang, Linna Xie, Xiaojing Yan, Haifeng Zhao, Ki Hyon Kim, Yuankai Shi

Blood (2023) 142 (Supplement 1): 7354.

https://doi.org/10.1182/blood-2023-179638

Published: 2023

Journal Articles

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Blood (2023) 142 (Supplement 1): 4458.

https://doi.org/10.1182/blood-2023-181385

Published: 2023

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Journal Articles

Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker

Shihua Zhao, Yao Liu, Zunmin Zhu, Jianxia He, Lihong Liu, Xiaobo Wang, Yuxia Zhao, Chongling Hu, Xiaoli Yuan, Sijun Bai, Ye Geng, Wenrong Huang

Blood (2022) 140 (Supplement 1): 1338–1339.

https://doi.org/10.1182/blood-2022-165710

Published: 2022

Journal Articles

Limited Long-Term Benefit of Upfront Autologous Stem Cell Transplant on Survival in Severe Renal Impairment in Multiple Myeloma in Novel Drug Era, a Retrospective Multi-Center Study in China

Huixing Zhou, Yuan Jian, Weiwei Xie, Yuan Ren, Zhiyao Zhang, Guangzhong Yang, Chuanying Geng, Jing Jia, Wenming Chen, Jian Li, Wenrong Huang, Xinan Cen, Wen Gao

Blood (2022) 140 (Supplement 1): 12504–12505.

https://doi.org/10.1182/blood-2022-166445

Published: 2022

Journal Articles

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2022) 140 (Supplement 1): 10167–10169.

https://doi.org/10.1182/blood-2022-159361

Published: 2022

Journal Articles

Impact of Dialysis Dependence on Survival for Multiple Myeloma Patients with Renal Impairment: A Multicenter Retrospective Study in China

Yuan Jian, Huixing Zhou, Weiwei Xie, Yuan Ren, Zhiyao Zhang, Guangzhong Yang, Chuanying Geng, Jing Jia, Wenming Chen, Jian Li, Wenrong Huang, Xinan Cen, Wen Gao

Blood (2022) 140 (Supplement 1): 12635–12636.

https://doi.org/10.1182/blood-2022-159950

Published: 2022

Journal Articles

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

Li Bao, Min-qiu Lu, Peng Liu, Yu-Tong Wang, Junling Zhuang, Mei Zhang, Zhongjun Xia, Zhenling Li, Ying Yang, Zhenyu Yan, Hongmei Jing, Wenming Chen, Hebing Zhou, Rong Fu, Yuping Gong, Wenrong Huang, Yongqing Zhang

Blood (2022) 140 (Supplement 1): 12564–12565.

https://doi.org/10.1182/blood-2022-168068

Published: 2022

Journal Articles

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Blood (2022) 140 (Supplement 1): 3609–3611.

https://doi.org/10.1182/blood-2022-158675

Published: 2022

Journal Articles

Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Jun Ma, Yuqin Song, Yan Xie, Hui-Lai Zhang, Yuerong Shuang, Zhigang Peng, Li Fei, Yunhong Huang, Weili Zhao, Wenrong Huang, Yali Pan, Mingying Liu, Feiwu Ran, Hui Feng, Sheng Yao, Patricia Keegan, Jianjun Zou, Jun Zhu

Blood (2022) 140 (Supplement 1): 3716–3717.

https://doi.org/10.1182/blood-2022-157497

Published: 2022

Journal Articles

A Multi-Center Epidemiological and Prognostic Analysis of Cytogenetic Abnormalities in a Cohort of 1015 Chinese Patients with Newly-Diagnosed Multiple Myeloma

Fengyan Jin, MD PhD, Guangxun Gao, MD, Yujun Dong, MD, Chunrui Li, MD PhD, Wenrong Huang, Limo Zhang, MD, Qiang Zhu, MD, Ruifeng Yuan, MD, Li Xu, MD, Yanjie Xu, MD, Qian Xu, Shaji K. Kumar, MD, Yun Dai, MD

Blood (2019) 134 (Supplement_1): 3094.

https://doi.org/10.1182/blood-2019-132076

Published: 2019

Journal Articles

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Kaini Shen, MD, Yujun Dong, MD, Weijun Fu, Sr., MD PhD, Yu Wu, MD, Zhongxia Huang, Yongqiang Wei, PhD, Chunrui Li, MD PhD, Chunyan Sun, MD PhD, Wenrong Huang, Huihan Wang, MD PhD, Congli Zhang, Huilei Miao, Lu Zhang, MD, Xinxin Cao, MD, Daobin Zhou, MD, Jian Li, MD

Blood (2019) 134 (Supplement_1): 1870.

https://doi.org/10.1182/blood-2019-122087

Published: 2019

Journal Articles

Prophylactic Modified Donor Lymphocyte Infusion after Allogeneic Peripheral Blood Stem Cell Transplantation for Very High-Risk Hematological Malignancies: Low Incidence of Relapse without Increasing the Risk of Graft-Versus-Host Disease

Xiaoning Gao, Shuhong Wang, Wenrong Huang, Honghua Li, Yu Jing, Liping Dou, Fei Li, Lili Wang, MD PhD, Xiaolin Lu, Jing Chen, MD, Lijun Wang, Xiangshu Jin, Li Yu, Daihong Liu

Blood (2017) 130 (Supplement 1): 2002.

https://doi.org/10.1182/blood.V130.Suppl_1.2002.2002

Published: 2017

NARROW

Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Efficacy of Zanubrutinib Combined with Immunochemotherapy in Newly Diagnosed MYD88-Mutated Diffuse Large B-Cell Lymphoma: A Retrospective Single-Center Study

Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R 2 ) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Daratumumab Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Upfront Autologous Stem Cell Transplant at First Complete Remission in Patients with Advanced-Stage Extra-Nodal NK/T Cell Lymphoma: A Multicenter Retrospective Study

Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: Psychological Burden and Influencing Factors from Mycosis Fungoides and Sézary Syndrome Patients in China

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker

Limited Long-Term Benefit of Upfront Autologous Stem Cell Transplant on Survival in Severe Renal Impairment in Multiple Myeloma in Novel Drug Era, a Retrospective Multi-Center Study in China

Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Impact of Dialysis Dependence on Survival for Multiple Myeloma Patients with Renal Impairment: A Multicenter Retrospective Study in China

Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Ixazomib, Pegylated Liposomal Adriamycin, and Dexamethasone(IDd) in Elderly Frail Newly Diagnosed Multiple Myeloma with GA Score ≥2: A Prospective Multicenter Study

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

A Multi-Center Epidemiological and Prognostic Analysis of Cytogenetic Abnormalities in a Cohort of 1015 Chinese Patients with Newly-Diagnosed Multiple Myeloma

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Prophylactic Modified Donor Lymphocyte Infusion after Allogeneic Peripheral Blood Stem Cell Transplantation for Very High-Risk Hematological Malignancies: Low Incidence of Relapse without Increasing the Risk of Graft-Versus-Host Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only